Skip to main content
SpringerLink
Log in

Botulinum toxin therapy for hyperhidrosis: reduction of injection site pain by nitrous oxide/oxygen mixtures

  • Neurology and Preclinical Neurological Studies - Original Article
  • Published:
Journal of Neural Transmission Aims and scope Submit manuscript

Abstract

Injection site pain (ISP) reduces compliance of botulinum toxin (BT) therapy considerably. We wanted to study whether nitrous oxide/oxygen (NOO, Livopan®, Linde Gas Therapeutics, Unterschleißheim, Germany) can reduce ISP in patients receiving intracutaneous BT injections for axillary or palmar hyperhidrosis (HH). The study followed an open-label design comparing intraindividually ISP in both axillae and/or both palms when NOO was applied or not during BT injections. BT efficacy was measured by the Hyperhidrosis Disease Severity Scale (HDSS) and by a 4-point Self-Assessment Scale. ISP was documented by a Visual Analogue Scale (VAS) and the Verbal Scale of Pain Intensity (VSPI), adverse effects by a Structuralised Interview (SI). Altogether 13 patients (age 34.1 ± 12.4 years, 9 females, 4 males) were studied. 11 BT treatments were for biaxillary and 3 for bipalmar HH. BT reduced biaxillary HH from HDSS 3.7 ± 0.5 to 1.0 ± 0 and bipalmar HH from 3.6 ± 0.6 to 1.0 ± 0. All patients reported ISP reduction by NOO. In axillary HH, NOO reduced ISP from 55.7 ± 12.7 to 12.8 ± 7.5 on the VAS (p < 0.05) and from 4.1 ± 0.3 to 0.7 ± 0.5 on the VSPI (p < 0.05), in bipalmar HH from 60.0 ± 10.0 to 13.3 ± 5.8 on the VAS (p < 0.05) and from 5.0 ± 0 to 1.3 ± 0.5 on the VSPI (p < 0.05). Adverse effects were not identified. NOO is a potent, non-sedative, quickly reversible and safe inhalative analgesic which reduces ISP considerably in patients receiving BT therapy for axillary and palmar HH thus substantially improving compliance of BT therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

Abbreviations

BT:

Botulinum toxin

NOO:

Nitrous oxide/oxygen

ISP:

Injection site pain

HDSS:

Hyperhidrosis Disease Severity Scale

VAS:

Visual Analogue Scale

VSPI:

Verbal Scale of Pain Intensity

SAS:

Self-Assessment Scale

SI:

Structuralised Interview

References

  • Campanati A, Lagalla G, Penna L, Gesuita R, Offidani A (2004) Local neural block at the wrist for treatment of palmar hyperhidrosis with botulinum toxin: technical improvements. J Am Acad Dermatol 5:345–348

    Article  Google Scholar 

  • Collado V, Nicolas E, Faulks D, Hannequin M (2007) A review of the safety of 50 % nitrous oxide/oxygen in conscious sedation. Expert Opin Drug Saf 6:559–571

    Article  CAS  PubMed  Google Scholar 

  • D’Arcy Y (2003) Pain assessment, Chapter 2. In: Iyer P (ed) Medical-Legal Aspects of Pain and Suffering. Lawyers and Judges Publishing Company, Tucson, AZ

  • Kontochristopoulous G, Gregoriou S, Zakopolou N, Rigopoulos D (2006) Cryoanalgesia with dichlorotetrafluroethane spray versus ice packs in patients treated with botulinum toxin-a for palmar hyperhidrosis: self-controlled study. Dermatol Surg 32:31–33

    Google Scholar 

  • Kouris A, Armyra K, Christodoulou C, Karimali P, Karypidis D, Kontochristopoulous G (2014) Quality of life in patients with focal hyperhidrosis before and after treatment with botulinum toxin A. ISRN Dermatol 2014:ID 308650

    Article  Google Scholar 

  • Lowe N, Campanati A, Bodokh I, Cliff S, Jaen P, Kreyden O, Naumann M, Offidani A, Vadoud J, Hamm H (2004) The place of botulinum toxin type A in the treatment of focal hyperhidrosis. Br J Dermatol 151:1115–1122

    Article  CAS  PubMed  Google Scholar 

  • Naumann M (2001) Evidence based medicine: botulinum toxin in focal hyperhidrosis. J Neurol 248:31–33

    Article  CAS  PubMed  Google Scholar 

  • Solish N, Bertucci V, Dansereau A, Hong HC, Lynde C, Lupin M, Smith KC, Storwick G, Canadian Hyperhidrosis Advisory Committee (2007) A comprehensive approach to the recognition, diagnosis, and severity-based treatment of focal hyperhidrosis: recommendations of the Canadian Hyperhidrosis Advisory Committee. Dermatol Surg 33:908–923

    CAS  PubMed  Google Scholar 

  • Strutton DR, Kowalski JW, Glaser DA, Stang PE (2004) US prevalence of hyperhidrosis and impact on individuals with axillary hyperhidrosis: results from a national survey. J Am Acad Dermatol 51:241–248

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Movement Disorders Section, Department of Neurology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany

    Lejla Paracka, Katja Kollewe, Reinhard Dengler & Dirk Dressler

Authors
  1. Lejla Paracka
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Katja Kollewe
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Reinhard Dengler
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Dirk Dressler
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dirk Dressler.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Paracka, L., Kollewe, K., Dengler, R. et al. Botulinum toxin therapy for hyperhidrosis: reduction of injection site pain by nitrous oxide/oxygen mixtures. J Neural Transm 122, 1279–1282 (2015). https://doi.org/10.1007/s00702-015-1372-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00702-015-1372-x

Keywords

Search

Navigation